iCAD traces its origins to 1984 ― a year of tremendous technological advancements: Dell Computers was founded, Apple introduced the Macintosh, and Sony released the Discman as the first portable CD player.[i],[ii],[iii] This year of inspiring innovation was the same year that Howard Howtek launched Howtek Inc., a technology company that initially specialized in developing, manufacturing, and marketing digitized systems and scanners. In 2001, the company began to specialize in computer-aided... Continue reading

Nashua, N.H. – January 13, 2020 – iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Nathaniel Dalton was appointed to its Board of Directors.

Mr. Dalton is one of the founders of the global asset management firm Affiliated Managers Group, Inc. (NYSE:AMG), where he remains a Director and Senior Advisor. Mr. Dalton held a range of executive positions at AMG, including General Counsel, Chief Operating Officer, President and Chief Executive O... Continue reading

World’s first and largest open AI Marketplace expands access to ProFound AI for U.S. radiologists, 80 percent of whom use Nuance’s radiology reporting system

NASHUA, NH -- December 4, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Breast Health Solution... Continue reading

Company Unveils New Initiative, ProFound AI Powered by Panorama, which will Enable Breast Imaging Intelligence Technology to Correlate Findings Over Time

NASHUA, N.H. and Chicago – December 2, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its Breast Health Solutions suite including the expanded ProFound AI™ platform in the iCAD exhibition booths (#3929 in the sout... Continue reading

NASHUA, N.H., Nov. 26, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Piper Healthcare Conference, taking place December 3-5, 2019 in New York City.

Presentation Details:

Date: 

December 5, 2019

Continue reading

NASHUA, N.H., Nov. 18, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Canaccord Genuity MedTech & Diagnostics Forum, taking place Thursday, November 21st in New York City.

Presentation Details:

Date: 

Thursday, November 21, 2019

Continued strong momentum for ProFound AI™ iCAD’s proprietary cancer detection AI technology

 Conference call today at 8:30 a.m. ET

NASHUA, N.H. – October 30, 2019 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions today reported its financial and operating results for the three and nine... Continue reading

With 1 in 8 women at risk of developing breast cancer in her lifetime[i], it’s important to know your personal risk and get screened regularly. Breast cancer screening has improved significantly in recent years, making it more important than ever for women to know about the latest advancements that can help doctors find cancers earlier, when they may be more easily treated. Before you book your next mammogram, talk to your doctor about your personal risks and what option is best for you.

Continue reading

NASHUA, N.H., Oct. 24, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter and nine-months ended September 30, 2019, before the market open, and host a conference call at 8:30am Eastern Time on Wednesday, October 30, 2019.

Wednesday, October 30th @ 8:30am ET

Domestic:

877-407-0784

iCAD to Showcase Entire ProFound AI Platform, including its Solutions for 2D Mammography and Digital Breast Tomosynthesis in Paris at Medical Conference

NASHUA, N.H. and PARIS – October 7, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the full ProFound AI™ platform will be featured in the iCAD exhibition booth (#226A) at the Journées Francophones de Rad... Continue reading

Company to exhibit ProFound AI for 2D and 3D Mammography in Europe

Nashua, N.H. and Budapest, Hungary – October 1, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will exhibit the ProFound AI™ platform, including ProFound AI™ for 2D Mammography and ProFound AI™ for Digital Breast Tomosynthesis (DBT) in the iCAD exhibition booth (#13) at the Eu... Continue reading

Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers

NASHUA, N.H. and CHICAGO – September 16, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electronic... Continue reading

iCAD, Inc. recently received the “Best New Radiology Solution” Award for the ProFound AI™ platform in the 2019 MedTech Breakthrough Awards Program. The program recognizes the top companies and solutions in the global health and medical technology industries; this year, over 3,500 nominations were considered from more than 15 countries around the world.

ProFound AI for Digital Breast Tomosynthesis (DBT) is the first and only FDA-cleared 3D tomosynthesis technology using artificial intelligence (AI). The technology was designed to ad... Continue reading

First and Only FDA-Cleared Digital Breast Tomosynthesis Software with Artificial Intelligence Clinically Proven to Enhance Breast Cancer Screening, Reduce False Positives and Slash Reading Time for Radiologists in Half

Nashua, N.H. – September 10, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of its reader study for ProFound AI™ fo... Continue reading

First and Only FDA-Cleared Artificial Intelligence Solution Supporting Breast Cancer Detection in 3D Tomosynthesis Recognized by Annual Awards Program

NASHUA, N.H – September 4, 2019 – iCAD, Inc. (“iCAD”) (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced MedTechBreakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market,... Continue reading

Conference call today at 8:30 a.m. ET

NASHUA, N.H. – August 1, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported financial results for the three and six months ended June 30, 2019.

Second Quarter 2019 Highli... Continue reading

NASHUA, N.H. – July 29, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2019, before the market open, and host a conference call at 8:30am Eastern Time on Thursday, August 1, 2019.

Thursday, August 1st @ 8:30am Eastern Time

Domestic:

877-407... Continue reading

Deep-learning, artificial intelligence technology assists radiologists in detecting breast cancer

Nashua, N.H. – July 11, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its advanced artificial intelligence technology and workflow solution, ProFound AI™ for 2D Mammography, re... Continue reading

iCAD’s Innovative ProFound AI™ Solution for Digital Breast Tomosynthesis offers high-performing workflow solution for radiologists

PHOENIX and NASHUA, N.H. (July 10, 2019) – SimonMed Imaging, one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States, announced today their implementation of the first FDA-cleared AI program for significantly enhancing early breast cancer detection for 3D mammo... Continue reading

NASHUA, N.H. – June 18, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 19 at 12:00pm ET and will participate in the Piper Jaffray Heartland Summit on Thursday, June 20 in Minneapolis, MN.

About iCAD, Inc.

Headquartered in Nashua,... Continue reading